The aim of this study was to review the post-operative and infectious complications and determine the risk factors associated with infections in cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC).
Patients and Methods:
Between October 2007 and December 2013, patients who underwent CRS and HIPEC with a curative intent were included in the study. The Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance System definitions were used to identify post-operative nosocomial infections.
Results:
One hundred and sixty-nine CRS and HIPEC procedures were performed. Overall, 155 complications were observed in 82 (48.5%) patients. Grade 3–4 morbidity rate was 25.5% (n = 43). Seventy infections occurred in 47 patients. Surgical site infection was the most common infectious complication. The most common micro-organism isolated from the cultures was Escherichia coli. Age (odds ratio [OR]1.039, confidence interval [CI] 1.006–1.073), the mean total number of staff scrubbing in the operation(OR 2.241, CI 1.415–3.548), and intensive care unit stay (OR 1.325, CI 0.953–1.842) were independent risk factors for infectious complications.
Conclusions:
Infectious complications are the most important cause of peri-operative morbidity and death in CRS and HIPEC. As well as patient and tumor characteristics, surgeon/center-related factors play an important role in infectious morbidity. Patients with peritoneal carcinomatosis should be considered as a complex oncologic group at high risk of infectious complications.
Get full access to this article
View all access options for this article.
References
1.
SugarbakerPH. Peritonectomy procedures. Surg Oncol Clin N Am, 2003; 12:703–727.
2.
VerwaalVJ, van RuthS, WitkampA, et al.Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol, 2005; 12:65–71.
3.
da SilvaRG, SugarbakerPH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg, 2006; 203:878–886.
4.
YanTD, MorrisDL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: Experimental therapy or standard of care?. Ann Surg, 2008; 248:829–835.
5.
GlehenO, KwiatkowskiF, SugarbakerPH, et al.Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multiinstitutional study. J Clin Oncol, 2004; 22:3284–3292.
6.
EliasD, GillyF, BoutitieF, et al.Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol, 2010; 28:63–68.
7.
BrücherLD, ItzhakA, BilchikA, et al.Carcinomatosis: Cytoreduction and heated intraperitoneal chemotherapy (HIPEC) versus palliation. In: Steele SR, Maykel JA, Champagne BJ (eds): Complexities in Colorectal Surgery. New York: Springer, 2015: 63–89.
8.
CaponeA, ValleM, ProiettiF, et al.Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol, 2007;1;96:507–513.
9.
JacquetP, SugarbakerPH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res, 1996; 15:49–58.
JarvisWR. Benchmarking for prevention: The Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance (NNIS) system experience. Infection, 2003; 31(Suppl 2):44–48.
12.
CharlsonM, SzatrowskiTP, PetersonJ, GoldJ. Validation of a combined comorbidity index. J Clin Epidemiol, 1994; 47:1245–1251.
13.
EliasD, LefevreJH, ChevalierJ, et al.Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol, 2009; 27:681–685.
14.
VerwaalVJ, van RuthS, de BreeE, et al.Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol, 2003; 21:3737–3743.
15.
LevineEA, Stewart JHIV, RussellGB, et al.Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Experience with 501 procedures. J Am Coll Surg, 2007; 204:943–953.
16.
SugarbakerPH, ChangD. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol, 1999; 6:727–731.
17.
CandaAE, SokmenS, TerziC, et al.Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol, 2013; 20:1082–1087.
18.
RovielloF, MarrelliD, NeriA, et al.Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): Postoperative outcome and risk factors for morbidity. World J Surg, 2006; 30:2033–2040.
19.
ChuaTC, YanTD, SaxenaA, MorrisDL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg, 2009; 249:900–907.
20.
KusamuraS, YounanR, BarattiD, et al.Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer, 2006; 106:1144–1153.
21.
GlehenO, OsinskyD, CotteE, et al.Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol, 2003; 10:863–869.
22.
Di MiceliD, AlfieriS, CaprinoP, et al.Complications related to hyperthermia during hyperthermic intraoperative intraperitoneal chemiotherapy (HIPEC) treatment. Do they exist?. Eur Rev Med Pharmacol Sci, 2012; 16:737–742.
23.
SugarbakerPH, AldermanR, EdwardsG, et al.Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol, 2006; 13:635–644.
24.
StephensAD, AldermanR, ChangD, et al.Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative chemotherapy using coliseum technique. Ann Surg Oncol, 1999; 6:790–796.
25.
ValleM, FedericiO, Carboniet al.Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: Proposal and results from a prospective protocol study of prevention, surveillance and treatment. Eur J Surg Oncol, 2014; 40:950–956.
26.
VelascoE, SoaresM, ByingtonR, et al.Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. Eur J Clin Microbiol Infect Dis, 2004; 23:596–602.
27.
BassettiM, MarchettiM, ChakrabartiA, et al.A research agenda on the management of intra-abdominal candidiasis: Results from a consensus of multinational experts. Intensive Care Med, 2013; 39:2092–2106.
28.
DaudtHM, CosbyC, DennisDL, et al.Nutritional and psychosocial status of colorectal cancer patients referred to an outpatient oncology clinic. Support Care Cancer. 2012; 20:1417–1423.
29.
VashiPG, GuptaD, LammersfeldCA, et al.The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. Nutr J, 2013; 12:118.
30.
MohamedF, MoranBJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: The importance of a learning curve. Cancer J, 2009; 15:196–199.
31.
CavaliereF, ValleM, De RosaB, et al.Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: Learning curve. (Ita) Suppl Tumori, 2005; 4:S119–S121.
32.
SmeenkRM, VerwaalVJ, ZoetmulderFA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg, 2007; 94:1408–1414.
33.
YanTD, LinksM, FransiS, et al.Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol, 2007; 14:2270–2280.
34.
MoranBJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf), 2006; 28:375–378.
35.
AndréassonH, LorantT, PahlmanL, et al.Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: Aspects of the learning curve. Eur J Surg Oncol, 2014; 40:930–936.
36.
KusamuraS, BarattiD, HutanuI, et al.The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am, 2012; 21:559–576.
